Table 1 Basic science trials of finerenone
From: Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms
Target | Organ and tissue | Model | Effect |
|---|---|---|---|
TNFa/TNFR1/CASPASE8 | Heart | High-fat diet/low-dose streptozotocin-induced diabetic rats | Reduce the apoptosis of cardiomyocytes [16] |
PPARγ/CD36 | Heart | High-fat diet/low-dose streptozotocin-induced diabetic rats | Improve lipid metabolism in cardiomyocytes; inhibit apoptosis and oxidative stress [16] |
GRK5 | H9c2 cardiomyocytes | Cells endogenously express the MR and GRK5 | Inhibit apoptosis, oxidative stress, and fibrosis [17] |
MR | Human coronary artery SMCs and umbilical vein ECs | Cells were incubated with aldosterone | Reduce SMC proliferation and EC apoptosis [18] |
PI3K/Akt/eNOS | Kidney | High-fat diet/streptozotocin-induced diabetic rats | Restore the mitophagy [19] |
MR | Vascular smooth muscle cells | Noninfarcted mice incubated with low-dose angiotensin-II | Inhibit oxidative stress [20] |
MR | Heart | Zucker fa/fa rats | Inhibit oxidative stress [21] |
MR | Heart | Obese ZSF1 rats | Attenuate cardiac diastolic dysfunction and improve cardiac perfusion [22] |